ECONOMIC AND BUSINESS MODELS
AMR CONTROL 2015 25
References
1.who. Research and Development to Meet Health Needs in Developing Countries:
Strengthening Global Financing and Coordination. Geneva: World Health
Organization, 2012.
2.unfpa. UN Commission on Life Saving Commodities for Women and Children.
Commissioners'Report New York: United Nations Population Fund; 2012 [cited 2014
28 October]. Available from:
http://www.unfpa.org/public/home/publications/pid/12042.
3.sertkaya A, Eyraud J, Birkenbach A, Franz C, Ackerley N, Overton V, et al. Analytical
Framework for Examining the Value of Antibacterial Products: Eastern Research
Group, Inc., report commissioned by the US Department of Health and Human
Services; 2014 [cited 2014 31 October]. Available from:
http://aspe.hhs.gov/sp/reports/2014/antibacterials/rpt_antibacterials.cfm.
4.who. Intellectual property rights, innovation and public health. Report by the
Secretariat Geneva: World Health Organization; 2003 [cited 2014 13 October].
Available from: http://apps.who.int/gb/archive/pdf_files/wha56/.
5.who. Public health, innovation and intellectual property rights Geneva: Report of the
Commission on Intellectual Property Rights, Innovation and Public Health. World
Health Organization; 2006 [cited 2014 10 November]. Available from:
http://www.who.int/intellectualproperty/documents/thereport/enpublichealthrepor
t.pdf?ua=1.
6.who. Global Strategy and Plan of Action on Public Health, Innovation and Intellectual
Property Geneva: World Health Organization; 2011 [cited 2014 10 November].
Available from: http://www.who.int/phi/publications/global_strategy_plan_action.pdf.
7.who. Research and Development - Coordination and Financing Geneva: Report of
the World Health Organization Expert Working Group on Research and Development
Financing; 2010 [cited 2014 24 December]. Available from:
http://www.who.int/phi/documents/ewg_report/en/.
8.Årdal C, Røttingen J-A, Alstadsæter A. Common characteristics of open source
software development and applicability for drug discovery: a systematic review. Health
Research Policy and Systems. 2011;9(36).
9.moon S, Jambert E, Childs M, von Schoen-Angerer T. A win-win solution?: A critical
analysis of tiered pricing to improve access to medicines in developing countries.
Globalization and Health. 2011;7(1):39.
10. Plahte J. Tiered pricing of vaccines: a win-win-win situation, not a subsidy. The Lancet
Infectious Diseases. 2005;5(1):58-63.
11. Bigdeli M, Peters DH, Wagner AK. Medicines in Health Systems:
Advancing access, affordability and appropriate use Geneva: Alliance for Health Policy
and Systems Research, World Health Organization; 2014 [cited 2014 10 November].
Available from: http://www.who.int/alliancehpsr/resources/atmflagshipreport.pdf?ua=1.
12. PCAST. Report to the President on Combating Antibiotic Resistance Washington
DC: President's Council of Advisors on Science and Technology; 2014 [cited 2014 10
November]. Available from: http://www.whitehouse.gov/sites/default/
files/microsites/ostp/PCAST/pcast_carb_report_sept2014.pdf.
13. So AD, Ruiz-Esparza Q, Gupta N, Cars O. 3Rs for innovating novel antibiotics: sharing
resources, risks, and rewards. British Medical Journal. 2012;344(e1782).